Financials
Financial year 2025
OCTIMET Oncology from Geel, company number BE0651853757, closed financial year 2025 with a result of € -95,727 after tax. For that financial year OCTIMET Oncology recorded a gross margin of € -16,540 and equity of € 243,628. Compared with financial year 2024, the result moved from € 179,816 to € -95,727. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 243,628
▼ 28% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -95,727
▼ still € 179,816 profit in 2024
Profit after tax over the fiscal year.
€ 29,192
▼ 82% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -15.5 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 5,816
▲ 170% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -19,537 | € 2,777 | € -56,278 | € -16,540 | ▲ € 39,738 |
| Profit after taxes | € -146,453 | € -131,817 | € 179,816 | € -95,727 | ▼ € 275,543 |
| Equity | € -4,036,423 | € -4,168,239 | € 339,354 | € 243,628 | ▼ 28% |
| Total debts | € 4,649,702 | € 4,643,641 | € 5,429 | € 9,125 | ▲ 68% |
| Cash | € 286,150 | € 224,896 | € 163,280 | € 29,192 | ▼ 82% |
| Retained profit | € -15,467,352 | € -15,599,168 | € -15,419,352 | € -15,515,078 | ▼ € 95,727 |
| Bank debt | € 4,643,641 | € 4,643,641 | € 0 | € 0 | |
| Balance sheet total | € 613,280 | € 475,402 | € 344,783 | € 252,753 | ▼ 27% |
Key figures of OCTIMET Oncology, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to OCTIMET Oncology?
What happened at OCTIMET Oncology in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Iker Huerga stepped down as director. NBB
- Timothy Perera stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 95,727 (▼ € 275,543 vs 2024). Source: NBB ↗
- Iker Huerga became a director. NBB
- Timothy Perera became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 146,453 loss in 2022 to € 95,727 loss in 2025.
Paid € 41,103 in corporate taxes since 2022.
Best year ever: 2024, with € 179,816 profit.
A new publication or filing at OCTIMET Oncology? We notify you, reason included.
Follow OCTIMET OncologyDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of DeuterOncology, Fund+, V-Bio Fund 1 comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
OCTIMET OncologyThe shares are held by DeuterOncology (100%), Fund+ (20.2%) and V-Bio Fund 1.
Directors
According to the 2025 annual accounts
Timothy Perera
Director
since 2024 · until 2030
Iker Huerga
Director
since 2026 · until 2032
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Oudepostelseweg 1
2440 Geel
Pieter van Reysschootlaan 2 box 104
9051 Gent
Active since 12 April 2016
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0651.853.757
- VAT number
- BE 0651.853.757
- Registered office
- Oudepostelseweg 1, 2440 Geel
- Names & denominations
- OCTIMET Oncology
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 12 April 2016
- Peppol
- Active · Active since 10 Mar 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied